Artemisinin inhibits neuronal ferroptosis in Alzheimer's disease models by targeting KEAP1. (PubMed, Acta Pharmacol Sin) - Sep 10, 2024 - "In hippocampal HT22 cells, pretreatment with artemisinin dose-dependently protected against Erastin-induced cell death with an EC50 value of 5.032 µM, comparable to the ferroptosis inhibitor ferrostatin-1 (EC50 = 4.39 µM)...Moreover, we demonstrated that artemisinin reversed Aβ1-42-induced ferroptosis, lipid peroxidation and glutathione depletion in HT22 cells, primary hippocampal neurons, and 3×Tg mice via the KEAP1-Nrf2 pathway. Our results demonstrate that artemisinin is a novel neuronal ferroptosis inhibitor that targets KEAP1 to activate the Nrf2-SLC7A11-GPX4 pathway."
Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Infectious Disease • Targeted Protein Degradation • GPX4 • KEAP1 • SLC7A11
|
|
Hong-Chang Gao; Ke-Qiang Ye; Marta Silva; Na Yang; Peng-Xi Deng; Qing Wang; Wen-Hua Zheng; Xin Meng
|